ClinicalTrials.gg
CompletedNCT07450521Updated Mar 30, 2026

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

A Phase 1 interventional study of MTX-463 and Placebo in Healthy Adult Male, sponsored by Mediar Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males. The study will consist of a single cohort comprising 8 healthy male participants, who on Day 1 will be randomly assigned to receive MTX-463 or matched placebo. Randomization will be in a 3:1 ratio such that 6 participants will receive MTX-463 and 2 will receive placebo. Participants randomized to MTX-463 will receive a dose of 250 mg of MTX-463.

Participants randomized to placebo will receive SC injections containing sodium chloride 0.9%. The injections will be given under the skin of the abdominal wall on Day 1. Blood will be drawn pre-dose on Day 1 for PK and antidrug antibodies (ADAs) and post-dose for PK at 6 and 24 hours. Participants will remain in the clinical research unit (CRU) for 24 hours after their injections, and then they will return for outpatient PK blood draws on Days 3 through 8, 15, and 22, with blood drawn for ADA assessment on Days 15 and 22. Each participant will undergo assessments at specified timepoints on Days 1 through 22 as detailed in Table 1. End-of-study procedures will be completed on Day 22 or upon early termination (ET). Local safety and tolerability at the injection site will be assessed at the time of the injections and for 24 hours afterward, and on Days 5, 8, 15 (±1 day), and 22 (±2 days) (EOS/ET).

02

Conditions studied

  • Healthy Adult Male

Keywords

  • MTX-463-I102
  • MTX-463
  • Healthy Volunteer
  • Healthy
  • Adult
  • Male
  • Monoclonal Antibody
  • MAB
03

In context

Lead sponsor

Mediar Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 18 to 60 years, inclusive
  • Able to understand the study and provide signed, written
  • Able to read and understand the language of the informed consent form and other study-related materials
  • Willing and able to complete all protocol-required study visits and procedures
  • Male participants with female partners of must use condoms during the treatment and until 125 days after the dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Any history of lung disease as determined by the Investigator
  • Any other concurrent active medical condition determined clinically significant by the Investigator
  • Any current skin conditions or rashes that involve the planned area of injection
  • (BMI) >30 kg/m2
  • Use of any systemic medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening
  • Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening
  • Current infection with , , or (HIV)
  • Planning to contribute to pregnancy during the study and up to 125 days after the participant's dose of study drug
  • History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 5 years of Screening
  • Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety
  • Known allergy to MTX-463 or any of its , or a history of a prior allergic reaction to a monoclonal antibody therapeutic
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    MTX-463

    MTX-463

    Biological: MTX-463

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalMTX-463

    MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. PK will be evaluated by area under the plasma concentration versus time curve from time zero to t (AUC0-t) of MTX-463

    Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)

    Time frame: 22 Days

  2. PK will be evaluated by Maximum Observed Plasma Concentration (Cmax) of MTX-463

    Unit of measure: ng/mL

    Time frame: 22 Days

  3. Comparisons of Maximum Observed Plasma Concentration (Cmax) of MTX-463 will be made to historical single-dose 4-mg/kg IV data.

    Unit of measure: ng/mL

    Time frame: 22 Days

  4. Comparisons of area under the plasma concentration versus time curve from time zero to t (AUC0-t) of MTX-463 will be made to historical single-dose 4-mg/kg IV data.

    Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)

    Time frame: 22 Days

Secondary outcomes

  1. Incidence of serious adverse events (SAEs)

    Number SAEs as defined by protocol criteria

    Time frame: 22 days

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Number of TEAEs summarized by seriousness and maximum severity as defined by protocol criteria

    Time frame: 22 days

  3. Incidence of Treatment Related Adverse Events (TRAEs)

    Number of TRAEs summarized by seriousness and maximum severity as defined by Protocol criteria

    Time frame: 22 days

  4. Clinically significant findings on clinical laboratory tests

    Clinically significant findings in hematology, clinical chemistry, urinalysis, and other protocol-specified laboratory parameters will be summarized. Units of Measure: Standard laboratory units (e.g., g/dL, mEq/L, mg/dL, increase by factor)

    Time frame: 22 days

  5. Descriptive statistics on vital signs.

    Descriptive statistics on temperature (Units: degrees Celcius), pulse rate (Units: beats per minute), respiratory rate (Units: breaths per minute), and blood pressure (Units: mmHg) will be assessed for change from Baseline, when applicable, and summarized by timepoint.

    Time frame: 22 Days

  6. Descriptive statistics on electrocardiograms (ECGs)

    Descriptive statistics on ECG parameters (including but not limited to PR interval, QRS interval, QT, QTcF, and RR) will be assessed for change from Baseline, when applicable, and summarized by timepoint. Units: msec

    Time frame: 22 Days

  7. Descriptive statistics on clinical laboratory tests.

    Descriptive statistics on hematology, clinical chemistry, urinalysis, and other protocol-specified laboratory parameters will be assessed for change from Baseline, when applicable, and summarized by timepoint. Units of Measure: Standard laboratory units (e.g., g/dL, mEq/L, mg/dL, increase by factor)

    Time frame: 22 Days

Other outcomes

  1. Incidence of injection site pain and injection site reactions

    Number of incidents of injection site pain and injection site reactions as assessed by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (V2.1)

    Time frame: 22 days

  2. Presence of Anti-Drug Antibodies (ADA)

    Presence of ADAs against MTX-463 in serum as assessed by a validated ELICA assay.

    Time frame: 22 days

  3. Signal inhibition in the confirmatory assay of Anti-Drug Antibodies (ADA)

    Signal inhibition in the confirmatory assay of Anti-Drug Antibodies (ADA) to assess the frequency with which positive signals are confirmed.

    Time frame: 22 days

  4. Titer of Anti-Drug Antibodies (ADA)

    Titer of ADAs against MTX-463 in serum as assessed by a validated ELICA assay. Units: titer units

    Time frame: 22 days

  5. Impact of Anti-Drug Antibodies (ADA)

    To assess whether the presence of ADA impacts the concentration of MTX-463 and adverse events.

    Time frame: 22 days

07

Study locations

1 site
  • Icon Slc Cru
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Mar 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 4, 2026
StartActual
Feb 18, 2026
Primary completionActual
Mar 11, 2026
CompletionActual
Mar 11, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450521
Lead sponsor
Mediar Therapeutics
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Feb 18, 2026
Primary completion
Mar 11, 2026
Completion
Mar 11, 2026
Last update
Mar 30, 2026

Study contacts

Todd Astor, MD
study chair · Mediar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MTX-463

Start the discussion